Hartenauer U, Thülig B, Diemer W, Lawin P, Fegeler W, Kehrel R, Ritzerfeld W
Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin, Westfälische Wilhelms-Universität Münster, FRG.
Crit Care Med. 1991 Apr;19(4):463-73. doi: 10.1097/00003246-199104000-00003.
To study the effect of enterally administered polymyxin E, tobramycin, and amphotericin B (selective flora suppression) on bacterial colonization, infection, resistance, and mortality rate.
Prospective, consecutive crossover controlled study.
Two surgical ICUs in a university hospital; ICU I with ten beds, ICU II with eight beds.
Two hundred patients entered the 1-yr trial. Fifty of 111 patients received selective flora suppression during the first 6 months in ICU I (test group), while 61 of 111 patients served as the control group in the following 6 months. In ICU II, 49 of 89 patients received no selective flora suppression in the first 6 months (control group), followed by 40 of 89 patients receiving selective flora suppression during the second 6-month period (test group).
The test group got a mixture of nonabsorbable antibiotics (paste and suspension) in the digestive tract. The control group received paste and suspension without antimicrobial agents. All 200 patients received cefotaxime during the first 4 days.
With the use of selective flora suppression, colonization with aerobic Gram-negative bacilli was significantly (p less than .01) reduced. There was also a significant reduction in nosocomial bronchopulmonary (ICU I and II; p less than .001) and urinary tract (ICU II; p less than .001) infections. The difference in mortality was not significant. There was no development of resistance against the antibiotics used during the limited period evaluated.
Selective flora suppression is effective in reducing secondary colonization by aerobic Gram-negative bacilli. Reduction of bronchopulmonary and urinary tract infections most likely occurs with colonization prevention.
研究经肠道给予多黏菌素E、妥布霉素和两性霉素B(选择性菌群抑制)对细菌定植、感染、耐药性及死亡率的影响。
前瞻性、连续交叉对照研究。
一所大学医院的两个外科重症监护病房;一号重症监护病房有10张床位,二号重症监护病房有8张床位。
200名患者进入为期1年的试验。111名患者中的50名在一号重症监护病房的前6个月接受选择性菌群抑制(试验组),而111名患者中的61名在接下来的6个月作为对照组。在二号重症监护病房,89名患者中的49名在头6个月未接受选择性菌群抑制(对照组),随后89名患者中的40名在第二个6个月期间接受选择性菌群抑制(试验组)。
试验组在消化道给予不可吸收抗生素混合物(糊剂和混悬液)。对照组接受不含抗菌剂的糊剂和混悬液。所有200名患者在头4天接受头孢噻肟治疗。
使用选择性菌群抑制后,需氧革兰阴性杆菌定植显著减少(p<0.01)。医院获得性支气管肺部感染(一号和二号重症监护病房;p<0.001)和尿路感染(二号重症监护病房;p<0.001)也显著减少。死亡率差异不显著。在评估的有限时间内,未出现对所用抗生素的耐药性。
选择性菌群抑制可有效减少需氧革兰阴性杆菌的继发定植。预防定植很可能会减少支气管肺部和尿路感染。